FTY720 attenuates excitotoxicity and neuroinflammation.

Area of Science:

• Neuroscience
• Pharmacology

Background:

• FTY720 (fingolimod) is an oral sphingosine-1-phosphate (S1P) receptor modulator approved for multiple sclerosis (MS).
• Its efficacy in MS is linked to immunosuppression via lymphopenia.
• FTY720's lipophilic nature allows it to cross the blood-brain barrier (BBB), suggesting potential direct neural effects.

Purpose of the Study:

• To investigate FTY720's neuroprotective potential against excitotoxic neuronal death.
• To determine if FTY720 acts directly on neurons or indirectly via modulating inflammation.

Main Methods:

• In vitro: Primary neuronal and organotypic cultures treated with NMDA to induce excitotoxicity; FTY720 effects on neuronal survival assessed.
• In vivo: Sprague-Dawley rats received intracerebroventricular kainic acid (KA) to model neurodegeneration and inflammation; FTY720 administered intracerebroventricularly and intraperitoneally.
• Microglial cultures treated with LPS to assess FTY720's modulation of microglial responses and stress signaling pathways (p38, JNK1/2 MAPKs).

Main Results:

• FTY720 significantly reduced excitotoxic neuronal death in vitro.
• In vivo, FTY720 administration attenuated KA-induced neurodegeneration and microgliosis in the hippocampus.
• FTY720 negatively modulated p38 MAPK in LPS-activated microglia but did not affect JNK1/2 activation.

Conclusions:

• FTY720 exhibits neuroprotective properties against excitotoxin-induced neuronal damage.
• FTY720 acts as a negative modulator of neuroinflammation.
• The p38 MAPK stress signaling pathway in microglia is a key target for FTY720's neuroprotective and anti-inflammatory actions.